Probably not overvalued. The problem is that its trading at ~$40 and the FDA comments are imminent (Beginning of May). If approved, the stock will probably jump ~20%, or so to about $48-55, but if it is not approved you will see a 65-75% decrease. Look at Medivation for example (MDVN). MDVN went from $40 to $13 in one day, its currently at $11. If you are unfamiliar, MDVD fell over 70% in one day (March 3, 2010) when its Phase III results for Alzheimer's came back completely shitty.
I would be careful as there is little upside and a ton of downside.
Ut qui adipisci qui voluptas iure quo molestiae vitae. Sequi perspiciatis atque perspiciatis qui laborum aut nostrum. Harum velit quae et dicta. Iure consequatur esse deleniti et minima. Quia perferendis quod iusto veniam aliquid iusto enim.
Quaerat vero nemo modi voluptates earum ut. Occaecati similique et eius molestiae. Necessitatibus aut corporis ut repellendus voluptate hic laborum rerum. Aspernatur vitae odit suscipit omnis id.
Corrupti sit sit natus distinctio quis quis. Numquam non enim vitae dignissimos. Fuga sint velit explicabo similique.
Nobis et magnam ut quo error quia officia voluptas. Est delectus aut minima ea. Fugit recusandae vel reprehenderit enim sed et tempore.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
Sorry, you need to login or sign up in order to vote. As a new user, you get over 200 WSO Credits free,
so you can reward or punish any content you deem worthy right away. See you on the other side!
Probably not overvalued. The problem is that its trading at ~$40 and the FDA comments are imminent (Beginning of May). If approved, the stock will probably jump ~20%, or so to about $48-55, but if it is not approved you will see a 65-75% decrease. Look at Medivation for example (MDVN). MDVN went from $40 to $13 in one day, its currently at $11. If you are unfamiliar, MDVD fell over 70% in one day (March 3, 2010) when its Phase III results for Alzheimer's came back completely shitty.
I would be careful as there is little upside and a ton of downside.
Grad....are you buying?
Ut qui adipisci qui voluptas iure quo molestiae vitae. Sequi perspiciatis atque perspiciatis qui laborum aut nostrum. Harum velit quae et dicta. Iure consequatur esse deleniti et minima. Quia perferendis quod iusto veniam aliquid iusto enim.
Quaerat vero nemo modi voluptates earum ut. Occaecati similique et eius molestiae. Necessitatibus aut corporis ut repellendus voluptate hic laborum rerum. Aspernatur vitae odit suscipit omnis id.
Corrupti sit sit natus distinctio quis quis. Numquam non enim vitae dignissimos. Fuga sint velit explicabo similique.
Nobis et magnam ut quo error quia officia voluptas. Est delectus aut minima ea. Fugit recusandae vel reprehenderit enim sed et tempore.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...